Cargando…

Financial sustainability of payment models for office-based opioid treatment in outpatient clinics

BACKGROUND: Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Despite evidence supporting its effectiveness and cost-effectiveness, uptake of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodgkin, Dominic, Horgan, Constance, Bart, Gavin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256208/
https://www.ncbi.nlm.nih.gov/pubmed/34225785
http://dx.doi.org/10.1186/s13722-021-00253-7
_version_ 1783718055289815040
author Hodgkin, Dominic
Horgan, Constance
Bart, Gavin
author_facet Hodgkin, Dominic
Horgan, Constance
Bart, Gavin
author_sort Hodgkin, Dominic
collection PubMed
description BACKGROUND: Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Despite evidence supporting its effectiveness and cost-effectiveness, uptake of the OBOT model has been relatively slow. One important barrier to faster diffusion of OBOT may be the financial challenges facing clinics that could adopt it. METHODS: We review key features and variants of the OBOT model, then discuss different approaches that have been used to fund it, and the findings from previous economic analyses of OBOT’s impact on organizational finances. We conclude by discussing the implications of these analyses for the financial sustainability of the OBOT delivery model. RESULTS: Like other novel services, OBOT poses challenges for providers due to its reliance on services which are ‘non-billable’ in a fee-for-service environment. A variety of approaches exist for covering the non-billable costs, but which approaches are feasible depends on local payer policies. The scale of the challenges varies with clinic size, organizational affiliations and the policies of the state where the clinic operates. Small clinics in a purely fee-for-service environment may be particularly challenged in pursuing OBOT, given the need to fund a dedicated staff and extra administrative work. The current pandemic may pose both opportunities and challenges for the sustainability of OBOT, with expanded access to telemedicine, but also uncertainty about the durability of the expansion. CONCLUSION: The reimbursement environment for OBOT delivery varies widely around the US, and is evolving as Medicare (and possibly other payers) introduce alternative payment approaches. Clinics considering adoption of OBOT are well advised to thoroughly investigate these issues as they make their decision. In addition, payers will need to rethink how they pay for OBOT to make it sustainable.
format Online
Article
Text
id pubmed-8256208
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82562082021-07-06 Financial sustainability of payment models for office-based opioid treatment in outpatient clinics Hodgkin, Dominic Horgan, Constance Bart, Gavin Addict Sci Clin Pract Review BACKGROUND: Office-Based Opioid Treatment (OBOT) is a delivery model which seeks to make medications for opioid use disorder (MOUD), particularly buprenorphine, widely available in general medical clinics and offices. Despite evidence supporting its effectiveness and cost-effectiveness, uptake of the OBOT model has been relatively slow. One important barrier to faster diffusion of OBOT may be the financial challenges facing clinics that could adopt it. METHODS: We review key features and variants of the OBOT model, then discuss different approaches that have been used to fund it, and the findings from previous economic analyses of OBOT’s impact on organizational finances. We conclude by discussing the implications of these analyses for the financial sustainability of the OBOT delivery model. RESULTS: Like other novel services, OBOT poses challenges for providers due to its reliance on services which are ‘non-billable’ in a fee-for-service environment. A variety of approaches exist for covering the non-billable costs, but which approaches are feasible depends on local payer policies. The scale of the challenges varies with clinic size, organizational affiliations and the policies of the state where the clinic operates. Small clinics in a purely fee-for-service environment may be particularly challenged in pursuing OBOT, given the need to fund a dedicated staff and extra administrative work. The current pandemic may pose both opportunities and challenges for the sustainability of OBOT, with expanded access to telemedicine, but also uncertainty about the durability of the expansion. CONCLUSION: The reimbursement environment for OBOT delivery varies widely around the US, and is evolving as Medicare (and possibly other payers) introduce alternative payment approaches. Clinics considering adoption of OBOT are well advised to thoroughly investigate these issues as they make their decision. In addition, payers will need to rethink how they pay for OBOT to make it sustainable. BioMed Central 2021-07-05 2021 /pmc/articles/PMC8256208/ /pubmed/34225785 http://dx.doi.org/10.1186/s13722-021-00253-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Hodgkin, Dominic
Horgan, Constance
Bart, Gavin
Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title_full Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title_fullStr Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title_full_unstemmed Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title_short Financial sustainability of payment models for office-based opioid treatment in outpatient clinics
title_sort financial sustainability of payment models for office-based opioid treatment in outpatient clinics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256208/
https://www.ncbi.nlm.nih.gov/pubmed/34225785
http://dx.doi.org/10.1186/s13722-021-00253-7
work_keys_str_mv AT hodgkindominic financialsustainabilityofpaymentmodelsforofficebasedopioidtreatmentinoutpatientclinics
AT horganconstance financialsustainabilityofpaymentmodelsforofficebasedopioidtreatmentinoutpatientclinics
AT bartgavin financialsustainabilityofpaymentmodelsforofficebasedopioidtreatmentinoutpatientclinics